US biopharmaceutical company Amphastar Pharmaceuticals has announced a multi-year expansion of its manufacturing operations at its headquarters in Rancho Cucamonga, California.

The company aims to quadruple production capacity at the site over the next three to five years, marking the most significant investment in domestic infrastructure in its history.

According to the company, this expansion reinforces its commitment to domestic pharmaceutical manufacturing and strengthening supply chain resilience.

The initiative will include a new state-of-the-art production plant, expanded automation, and the integration of advanced technologies to support the development and manufacture of critical medications, including supporting the production of new pipeline candidates.

"Expanding our domestic manufacturing footprint is not only a strategic milestone for Amphastar but a reaffirmation of our commitment to producing essential medicines right here in the United States," said Dr. Jack Zhang, Amphastar's President and CEO.

"All of our finished pharmaceutical products are proudly manufactured in the US, and this long-term investment strengthens the commitment, enhancing our ability to deliver greater flexibility, agility, and quality to the healthcare providers and patients who depend on our products every day,” he added.

Amphastar also emphasised its continued collaboration with government partners at all levels to ensure sustainable growth, workforce development, and alignment with economic and public health priorities.

Headquartered in California, Amphastar Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets complex generic and proprietary injectable, inhalation, and intranasal products. The company also sells insulin active pharmaceutical ingredients (APIs).